JP2021515568A5 - - Google Patents
Info
- Publication number
- JP2021515568A5 JP2021515568A5 JP2020547415A JP2020547415A JP2021515568A5 JP 2021515568 A5 JP2021515568 A5 JP 2021515568A5 JP 2020547415 A JP2020547415 A JP 2020547415A JP 2020547415 A JP2020547415 A JP 2020547415A JP 2021515568 A5 JP2021515568 A5 JP 2021515568A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- composition according
- acd25
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642218P | 2018-03-13 | 2018-03-13 | |
| US201862642243P | 2018-03-13 | 2018-03-13 | |
| US201862642248P | 2018-03-13 | 2018-03-13 | |
| US201862642230P | 2018-03-13 | 2018-03-13 | |
| US201862642232P | 2018-03-13 | 2018-03-13 | |
| GBGB1804029.5A GB201804029D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| US62/642,218 | 2018-03-13 | ||
| GBGB1804027.9A GB201804027D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GB1804027.9 | 2018-03-13 | ||
| US62/642,243 | 2018-03-13 | ||
| GB1804028.7 | 2018-03-13 | ||
| GBGB1804028.7A GB201804028D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
| GB1804029.5 | 2018-03-13 | ||
| EPPCT/EP2018/056312 | 2018-03-13 | ||
| US62/642,230 | 2018-03-13 | ||
| US62/642,248 | 2018-03-13 | ||
| US62/642,232 | 2018-03-13 | ||
| PCT/EP2019/056247 WO2019175215A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cd25 for tumour specific cell depletion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515568A JP2021515568A (ja) | 2021-06-24 |
| JP2021515568A5 true JP2021515568A5 (2) | 2022-03-18 |
Family
ID=67903878
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Country Status (14)
| Country | Link |
|---|---|
| US (11) | US10752691B2 (2) |
| EP (8) | EP3765502B1 (2) |
| JP (8) | JP7474701B2 (2) |
| KR (3) | KR20200131286A (2) |
| CN (8) | CN112020512B (2) |
| AU (3) | AU2019233575A1 (2) |
| BR (3) | BR112020016519A2 (2) |
| CA (3) | CA3088246A1 (2) |
| CR (3) | CR20200465A (2) |
| MA (1) | MA51993A (2) |
| PE (3) | PE20210288A1 (2) |
| SG (3) | SG11202008733YA (2) |
| TW (3) | TW201938588A (2) |
| WO (8) | WO2019175220A1 (2) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| KR20190017735A (ko) * | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| CN108795858A (zh) * | 2017-04-28 | 2018-11-13 | 深圳宾德生物技术有限公司 | 高抗癌活性t细胞的筛选方法和应用 |
| US10752691B2 (en) | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| EP3972997A1 (en) * | 2019-05-20 | 2022-03-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Novel anti-cd25 antibodies |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| JP2023525060A (ja) | 2020-05-14 | 2023-06-14 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| KR20230107641A (ko) * | 2020-11-13 | 2023-07-17 | 아이바이오, 인크. | Cd25 항체 |
| JP2024504547A (ja) * | 2020-11-20 | 2024-02-01 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 抗ｃｄ２５抗体 |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| JP2024505556A (ja) | 2021-02-02 | 2024-02-06 | ラクテン・メディカル，インコーポレイテッド | がん、腫瘍および腫瘍細胞の局所および全身処置のための方法 |
| KR20230154012A (ko) * | 2021-03-01 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 신규 바이오마커 및 이의 용도 |
| JP2024532790A (ja) | 2021-08-09 | 2024-09-10 | 南京▲諾▼艾新生物技▲術▼有限公司 | 組換え抗ヒトｃｄ２５抗体及びその使用 |
| US12129302B2 (en) | 2021-08-25 | 2024-10-29 | Ibio, Inc. | Anti-CD-25 antibody |
| US20240352136A1 (en) | 2021-09-02 | 2024-10-24 | Hoffmann-La Roche Inc. | Antibodies for the treatment of aml |
| EP4395823A4 (en) * | 2021-09-03 | 2025-07-16 | Novarock Biotherapeutics Ltd | BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN |
| TW202340250A (zh) | 2022-01-17 | 2023-10-16 | 大陸商諾納生物（蘇州）有限公司 | 標靶ｃｄ２５的抗體及其製備方法和應用 |
| EP4514388A1 (en) | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| CN115197321B (zh) * | 2022-06-02 | 2023-08-18 | 四川大学 | 靶向cd25的抗体及其用途 |
| CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| EP4547274A1 (en) * | 2022-06-30 | 2025-05-07 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd25-specific antibodies and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
| WO2024165454A1 (en) | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Combination therapy and uses thereof |
| TW202444757A (zh) * | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| TW202444760A (zh) * | 2023-03-29 | 2024-11-16 | 日商第一三共股份有限公司 | 抗ｃｄ２５抗體及抗ｃｄ２５抗體－藥物複合體 |
| WO2024213046A1 (en) * | 2023-04-11 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cd25 antibody and uses thereof |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026006708A2 (en) * | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026002198A1 (zh) * | 2024-06-28 | 2026-01-02 | 百奥泰生物制药股份有限公司 | 抗cd25抗体及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| JP2006517970A (ja) | 2003-02-14 | 2006-08-03 | ユニバーシティ オブ サザン カリフォルニア | 癌免疫療法のための組成物及び方法 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CA2585776A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| AU2007271398B2 (en) | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| AR064801A1 (es) | 2006-08-18 | 2009-04-29 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| EP2480671B8 (en) | 2009-09-22 | 2015-10-28 | ProBioGen AG | Process for producing molecules containing specialized glycan structures |
| WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| EP2378287A1 (en) * | 2010-04-15 | 2011-10-19 | TXCell | New method for isolating Tr1 cells |
| EP2595657A4 (en) | 2010-07-22 | 2015-09-23 | Univ California | ANTI-TUMOR ANTIGEN ANTIBODIES AND USE PROCESSES |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| HK1220470A1 (zh) | 2013-03-15 | 2017-05-05 | Abbvie Biotechnology Ltd. | 抗cd25抗体及其用途 |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| MX2015012563A (es) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anticuerpos anti-cd25 y sus usos. |
| SG11201509982UA (2) * | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3169363A4 (en) | 2014-07-16 | 2018-02-21 | F. Hoffmann-La Roche AG | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| BR112017001385B1 (pt) * | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| KR101940430B1 (ko) | 2014-08-07 | 2019-01-18 | 가꼬우호우징 효고 이카다이가쿠 | Il-18과 분자 표적 항체를 병용하는 암 치료약 |
| US11147652B2 (en) | 2014-11-13 | 2021-10-19 | Align Technology, Inc. | Method for tracking, predicting, and proactively correcting malocclusion and related issues |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| PE20171790A1 (es) * | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| CN115636880A (zh) * | 2015-10-23 | 2023-01-24 | 辉瑞有限公司 | 抗il-2抗体及其组合物和用途 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| RU2693661C2 (ru) * | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| CN109563170B (zh) * | 2016-06-10 | 2023-10-13 | 瑞泽恩制药公司 | 抗gitr抗体及其用途 |
| JP6831651B2 (ja) | 2016-07-04 | 2021-02-17 | 川崎重工業株式会社 | ワークの袋詰め装置 |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US11119165B2 (en) | 2017-06-28 | 2021-09-14 | North Carolina State University Office of Research Commercialization | Photonic band-gap resonator for magnetic resonance applications |
| EP3649153B8 (en) | 2017-07-06 | 2025-07-16 | Tusk Therapeutics Ltd | Fc optimised anti-cd25 antibodies for tumor specific cell depletion |
| UA129536C2 (uk) | 2018-03-13 | 2025-05-28 | Туск Терап'Ютікс Лтд | Анти-cd25 для виснаження пухлиноспецифічних клітин |
| US10752691B2 (en) | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| KR20200003558A (ko) | 2018-07-02 | 2020-01-10 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치 |
| KR102080909B1 (ko) | 2018-07-06 | 2020-02-24 | 한국수력원자력 주식회사 | 원자로의 해체 시스템 |
-
2019
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/en not_active Ceased
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 CN CN201980019241.1A patent/CN112020512B/zh active Active
- 2019-03-13 EP EP19709954.2A patent/EP3765502B1/en active Active
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/en active Pending
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 CN CN201980019248.3A patent/CN112020514B/zh active Active
- 2019-03-13 JP JP2020547326A patent/JP7563978B2/ja active Active
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko not_active Withdrawn
- 2019-03-13 CN CN201980019257.2A patent/CN112218891B/zh active Active
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/en active Active
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 KR KR1020207029221A patent/KR102909650B1/ko active Active
- 2019-03-13 CA CA3088246A patent/CA3088246A1/en not_active Abandoned
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 CA CA3088659A patent/CA3088659A1/en not_active Abandoned
- 2019-03-13 JP JP2020547331A patent/JP7563979B2/ja active Active
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/en active Active
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko not_active Withdrawn
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 EP EP19709956.7A patent/EP3765504B1/en active Active
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/en active Active
- 2019-03-13 CA CA3088671A patent/CA3088671A1/en active Pending
- 2019-03-13 EP EP19711315.2A patent/EP3765511B1/en active Active
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/en not_active Ceased
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/en not_active Ceased
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/en active Active
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/en not_active Ceased
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/en not_active Ceased
- 2019-03-13 CN CN201980019256.8A patent/CN112020516B/zh active Active
- 2019-03-13 CN CN201980019234.1A patent/CN112074536B/zh active Active
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/en not_active Ceased
- 2019-03-13 CN CN201980019247.9A patent/CN112020513B/zh active Active
- 2019-03-13 AU AU2019233581A patent/AU2019233581B2/en active Active
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 CN CN201980019235.6A patent/CN112041345B/zh active Active
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/en not_active Ceased
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/en not_active Ceased
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 JP JP2020547332A patent/JP7565797B2/ja active Active
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 CN CN201980019249.8A patent/CN112020515B/zh active Active
- 2019-03-13 JP JP2020547333A patent/JP7510348B2/ja active Active
-
2020
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515568A5 (2) | ||
| JP2021516975A5 (2) | ||
| JP2021515565A5 (2) | ||
| JP2021516973A5 (2) | ||
| JP2021533726A5 (2) | ||
| JP2021516974A5 (2) | ||
| JP2021516976A5 (2) | ||
| JP2021515566A5 (2) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2020515247A5 (2) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020522281A5 (2) | ||
| JP2020522280A5 (2) | ||
| Maleki et al. | Future prospects of monoclonal antibodies as magic bullets in immunotherapy | |
| JP2020533965A5 (2) | ||
| JP2022533538A5 (2) | ||
| JP2020182492A (ja) | 抗ｃｄ１３７抗体 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018510636A5 (2) | ||
| JP2018508475A (ja) | 抗ｐｄ−ｌ１抗体 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2020531003A5 (2) | ||
| JP2024536227A (ja) | がんの治療のためのｂ７－ｈ４抗体薬物コンジュゲート | |
| CN115812081A (zh) | 抗ctla-4抗体及其用途 | |
| Hale | Therapeutic antibodies—Delivering the promise? |